Developing Therapies for ARDS, SIRS, TBI and Spinal Cord Injury
Developing Therapies for ARDS, SIRS, TBI and Spinal Cord Injury
We have developed a suite of monoclonal antibodies targeting CD11d which plays a role in immune and inflammatory responses.
Our research has defined the role of CD11d in inflammation. Through the use of immunological, molecular and cell biological techniques, we have defined the phenotype and function of different monocyte subsets that infiltrate the site of inflammation.
The second focus of our research is the development of novel therapeutic vaccine approaches for cancer. The current emphasis is in developing antigen presenting cell-based therapeutic vaccines with a particular interest in dendritic cells.
Sign up to hear from us.
Our lab has defined certain targets and their role in important disease indications. From that discovery we have filed patents and perform preclinical drug development studies.
Once the target has been identified we validate drug candidates and prepare them for clinical evaluation through a network of trusted partners and service providers.
Once we have performed the necessary regulatory steps through the proper clinical phases we are prepared to conduct the necessary studies for eventual market approval and market launch.
Please send us a message or call us for an appointment.
507 Billybrook Crescent, London, Ontario N5X 2Y9, Canada
100 Perth Dr, London, ON N6A 5K8
Rescue Bio Inc.
Copyright © 2022 Rescue Bio Inc. - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.